Sight Sciences

SGHTPre-clinical

Sight Sciences is a publicly traded medical technology company dedicated to advancing the treatment of prevalent eye diseases like glaucoma and dry eye. The company has successfully commercialized two proprietary, minimally invasive surgical and non-surgical systems that address significant unmet needs in ophthalmology. Its strategy focuses on expanding clinical evidence, driving physician adoption, and improving patient access to its transformative technologies. With a foundation in innovative engineering, Sight Sciences seeks to establish new standards of care in the global eye care market.

Market Cap

$187.4M

SGHT · Stock Price

USD 3.479.98 (-74.21%)

Historical price data

AI Company Overview

Technology Platform

Develops proprietary, minimally invasive medical device platforms for ophthalmology, focusing on mechanistic approaches to treat diseases like glaucoma (via ab interno surgical systems) and dry eye (via targeted eyelid therapy systems).

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
Latanoprost plus adjunctive glaucoma medication	Primary Open Angle Glaucoma	Approved
Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion	Dry Eye	Pre-clinical

Opportunities

Significant opportunities exist in penetrating the large, underserved global markets for glaucoma and dry eye disease.

Growth can be driven by expanding clinical evidence to support earlier intervention, increasing surgeon adoption of minimally invasive procedures, and securing broader insurance reimbursement.

International market expansion represents a further long-term growth vector.

Risk Factors

Key risks include slower-than-expected commercial adoption against established competitors, changes in healthcare reimbursement policies that limit procedure coverage, potential for new competitive products to enter the market, and the company's current reliance on two primary products for all revenue, coupled with ongoing net losses and cash consumption.

Competitive Landscape

Sight Sciences competes in the glaucoma device market against companies like Alcon, Glaukos, and New World Medical, and in the dry eye device market against Johnson & Johnson (TearScience/Lipiflow). Its differentiation is based on the unique design of its OMNI (facilitating dual ab interno procedures) and TearCare (wearable, open-eye) systems, supported by clinical data aimed at demonstrating superior efficacy, safety, and patient experience.